Medicure Pharma is currently evaluating the safety and efficacy of TARDOXAL® to treat patients with tardive dyskinesia.


Tardive Dyskinesia

Tardive dyskinesia is a serious movement disorder resulting from long-term treatment with antipsychotic medications. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements, and can also be accompanied by psychotic symptoms of depression, and feelings of anger and embarrassment. Tardive dyskinesia is associated with poor quality of life and increased medical morbidity and mortality, however the mechanisms involved in the pathogenesis of tardive dyskinesia are poorly understood.


Clinical Trial(s)

Medicure has filed an FDA IND and conducted a 12-week, randomized, double-blind, placebo-controlled, parallel group comparative study to evaluate the safety and efficacy of TARDOXAL in the treatment of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders. Medicure is evaluating further clinical studies to pursue.


Contact Information:

Reuben Saba, PhD
VP, Medical and Business Affairs
Email: rsaba@medicure.com

Recent News

Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency

Clinical Trials: MC-1

Medicure is conducting the MEND-PNPO study, a Phase 3 study to assess the safety and efficacy of MC-1 in patients with confirmed PNPO deficiency via genetic analysis.